The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial
| Autor: | Olivia M Dean, Gin S Malhi, Ian Schapkaitz, Clarissa Severino Gama, Flávio Kapczinski, Karen Hewitt, Sue M. Cotton, Michael Berk, Seetal Dodd, H. Cobb, Ashley I. Bush, Christine Allwang, Brisa Simoes Fernandes, Sue Jeavons, Kristy Kohlmann |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder Placebo-controlled study Placebo Severity of Illness Index Antimanic Agents Internal medicine medicine Humans Bipolar disorder Psychiatry Depressive Disorder Depression Mood Disorders Free Radical Scavengers Middle Aged Free radical scavenger medicine.disease Antidepressive Agents Acetylcysteine Clinical trial Psychiatry and Mental health Clinical Psychology Treatment Outcome Mood disorders Adjunctive treatment Quality of Life Female medicine.symptom Psychology Mania |
| Zdroj: | Journal of Affective Disorders. 135:389-394 |
| ISSN: | 0165-0327 |
| DOI: | 10.1016/j.jad.2011.06.005 |
| Popis: | Background Evidence is accumulating to support the presence of redox dysregulation in a number of psychiatric disorders, including bipolar disorder. This dysregulation may be amenable to therapeutic intervention. Glutathione is the predominant non-enzymatic intracellular free radical scavenger in the brain, and the most generic of all endogenous antioxidants in terms of action. N-acetylcysteine (NAC) is a glutathione precursor that effectively replenishes brain glutathione. Given the failure of almost all modern trials of antidepressants in bipolar disorder to demonstrate efficacy, and the limited efficacy of mood stabilisers in the depressive phase of the disorder, this is a major unmet need. Method This study reports data on the treatment of 149 individuals with moderate depression during the 2 month open label phase of a randomised placebo controlled clinical trial of the efficacy of 1 g BID of NAC that examined the use of NAC as a maintenance treatment for bipolar disorder. Results In this trial, the estimated mean baseline Bipolar Depression Rating Scale (BDRS) score was 19.7 (SE = 0.8), and the mean BDRS score at the end of the 8 week open label treatment phase was 11.1 (SE = 0.8). This reduction was statistically significant (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect